Rituxan Hycela (rituximab/hyaluronidase human) 1400 mg and 23,400 units is used to treat specific blood cancers and autoimmune conditions. It combines rituximab, which targets CD20-positive B cells, with hyaluronidase to enhance absorption and allow subcutaneous administration. It is primarily indicated for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia. By depleting B cells, Rituxan Hycela helps in reducing disease activity, providing a convenient alternative to intravenous infusions and simplifying treatment protocols.

RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

- Follicular Lymphoma (FL) (1.1)

• Relapsed or refractory, follicular lymphoma as a single agent Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single- agent maintenance therapy

• Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy

- Diffuse Large B-cell Lymphoma (DLBCL) (1.2)

• Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens

- Chronic Lymphocytic Leukemia (CLL) (1.3)

• Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)